Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
12
12
2020
accepted:
23
02
2021
pubmed:
24
4
2021
medline:
22
7
2021
entrez:
23
4
2021
Statut:
ppublish
Résumé
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area. We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020. Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36-62 years; range, 17-95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%. Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.
Sections du résumé
BACKGROUND AND PURPOSE
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area.
MATERIALS AND METHODS
We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020.
RESULTS
Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36-62 years; range, 17-95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%.
CONCLUSIONS
Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.
Identifiants
pubmed: 33888450
pii: ajnr.A7134
doi: 10.3174/ajnr.A7134
pmc: PMC8324265
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1196-1200Informations de copyright
© 2021 by American Journal of Neuroradiology.
Références
Pract Neurol. 2020 Oct 8;:
pubmed: 33033161
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Neurointerv Surg. 2018 Aug;10(8):803-810
pubmed: 29871990
J Neurol. 2021 Jul;268(7):2331-2338
pubmed: 33026520
J Neuroradiol. 2021 Feb;48(1):65-67
pubmed: 32603768
Crit Care. 2020 Jul 11;24(1):419
pubmed: 32653019
SN Compr Clin Med. 2020 Oct 4;:1-5
pubmed: 33043250
Rev Neurol. 2020 May 16;70(10):391-392
pubmed: 32390132
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Stroke. 1996 Aug;27(8):1304-5
pubmed: 8711791
J Neurol Sci. 2020 Nov 15;418:117118
pubmed: 32977228
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
Blood. 2014 Sep 11;124(11):1715-26
pubmed: 25037630
BMJ Case Rep. 2020 Aug 11;13(8):
pubmed: 32784243
J Neuroradiol. 2021 Mar;48(2):121-124
pubmed: 32437707
J Med Virol. 2020 Jun;92(6):552-555
pubmed: 32104915
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Rev Neurol (Paris). 2020 Jun;176(6):521-523
pubmed: 32414532
Cardiovasc Res. 2020 May 1;116(6):1097-1100
pubmed: 32227090
Br J Hosp Med (Lond). 2020 Sep 2;81(9):1-4
pubmed: 32990081
Thromb Res. 2020 Sep;193:166-169
pubmed: 32707275
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Neuroradiology. 2020 Jun;62(6):647-648
pubmed: 32342126
Stroke. 2011 Apr;42(4):1158-92
pubmed: 21293023
AJNR Am J Neuroradiol. 2020 Aug;41(8):1370-1376
pubmed: 32554424
Eur J Case Rep Intern Med. 2020 Apr 29;7(5):001691
pubmed: 32399457
Int J Stroke. 2021 Jun;16(4):437-447
pubmed: 32852257
J Neurol Sci. 2020 Jul 15;414:116871
pubmed: 32422428
Ther Adv Neurol Disord. 2020 Mar 28;13:1756286420917830
pubmed: 32284735
Stroke Vasc Neurol. 2020 Sep;5(3):279-284
pubmed: 32616524
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
J Neurol Sci. 2020 Dec 15;419:117183
pubmed: 33075595
Cerebrovasc Dis Extra. 2020 Dec 7;10(3):174-180
pubmed: 33285543
Am J Respir Crit Care Med. 2020 May 15;201(10):P19-P20
pubmed: 32223716
Brain Behav Immun. 2020 Jul;87:18-22
pubmed: 32240762
AJNR Am J Neuroradiol. 2020 Aug;41(8):1377-1379
pubmed: 32554423
J Stroke Cerebrovasc Dis. 2020 Dec;29(12):105379
pubmed: 33254369
Case Rep Neurol. 2020 Sep 28;12(3):321-328
pubmed: 33173491
Int J Stroke. 2020 Jul;15(5):540-554
pubmed: 32362244
J Clin Neurosci. 2020 Sep;79:60-66
pubmed: 33070919
J Clin Neurosci. 2020 Sep;79:30-32
pubmed: 33070913
J Neurosurg. 2020 Sep 4;:1-4
pubmed: 32886922
Eur J Neurol. 2020 Sep;27(9):e38-e39
pubmed: 32503080
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
EBioMedicine. 2020 Sep;59:102939
pubmed: 32818804
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104989
pubmed: 32689590